2013-2014: Evolving Challenges for Value-Priced LDTs


Introduction -

In 2004, the Genomic Health Oncotype DX breast cancer molecular test was launched and within five years had substantially changed the standard of care for patients with early breast cancers. How has the marketplace changed in the past ten years, and what can companies expect when launching a new value-priced lab test today? Many conferences and publications have discussed “clinical utility” – how it should be defined, how it should be assessed, and what standards should be applied. However, there are many other changes in the payer industry and laboratory industry and in our healthcare system as a whole. This white paper examines major trends that directly impact the laboratory industry from the viewpoint of a startup company with a value priced diagnostic test.

An Informal Landscape For 2013/2014: Evolving Challenges For Value Priced LDTs -

The Successful national launch of the Genomic Health Oncotype DX Test was a landmark event in the evolution of the U.S. Laboratory industry. The Test was commercialized (with Collaboration from NIH investigators), priced at over $3000, And offered the potential to substantially impact the standard of care pathway for small breast cancers in patients nationwide. The Oncotype DX Test was not packaged as a commercial kit, but offered as a sole---source, very complex laboratory---developed test (LDT). As Documented in a 2010 White paper by the consultancy Health Advances, The road from its introduction to coverage for 80% Of U.S. insurance---covered lives took years --- From the market launch in 2004 (accompanied By a New England Journal publication) until early 2008. By The end of 2012, The company was profitable with income on the order of $10M Per year against revenue of some $200M Per year.

Please see full white paper below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:


Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.